<VariationArchive VariationID="2023946" VariationName="NM_000202.8(IDS):c.172del (p.Leu58fs)" VariationType="Deletion" Accession="VCV002023946" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2080572" VariationID="2023946">
      <GeneList>
        <Gene Symbol="IDS" FullName="iduronate 2-sulfatase" GeneID="3423" HGNC_ID="HGNC:5389" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149476988" stop="149505306" display_start="149476988" display_stop="149505306" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="148560294" stop="148586883" display_start="148560294" display_stop="148586883" Strand="-" />
          </Location>
          <OMIM>300823</OMIM>
          <Haploinsufficiency last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=IDS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=IDS">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000202.8(IDS):c.172del (p.Leu58fs)</Name>
      <CanonicalSPDI>NC_000023.11:149504224:G:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149504225" stop="149504225" display_start="149504225" display_stop="149504225" variantLength="1" positionVCF="149504224" referenceAlleleVCF="AG" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="148585755" stop="148585755" display_start="148585755" display_stop="148585755" variantLength="1" positionVCF="148585754" referenceAlleleVCF="AG" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>L58fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.148585755del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.148585755del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.149504225del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.149504225del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011900.3" sequenceAccession="NG_011900" sequenceVersion="3" change="g.6110del">
            <Expression>NG_011900.3:g.6110del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_147751.1" sequenceAccession="NG_147751" sequenceVersion="1" change="g.441del">
            <Expression>NG_147751.1:g.441del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000202.8" sequenceAccession="NM_000202" sequenceVersion="8" change="c.172del" MANESelect="true">
            <Expression>NM_000202.8:c.172del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000193.1" sequenceAccession="NP_000193" sequenceVersion="1" change="p.Leu58fs">
            <Expression>NP_000193.1:p.Leu58fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001166550.4" sequenceAccession="NM_001166550" sequenceVersion="4" change="c.-55del">
            <Expression>NM_001166550.4:c.-55del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_006123.5" sequenceAccession="NM_006123" sequenceVersion="5" change="c.172del">
            <Expression>NM_006123.5:c.172del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_006114.1" sequenceAccession="NP_006114" sequenceVersion="1" change="p.Leu58fs">
            <Expression>NP_006114.1:p.Leu58fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_104128.2" sequenceAccession="NR_104128" sequenceVersion="2" change="n.341del">
            <Expression>NR_104128.2:n.341del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000202.8(IDS):c.172del (p.Leu58fs) AND Mucopolysaccharidosis, MPS-II" Accession="RCV002862951" Version="2">
        <ClassifiedConditionList TraitSetID="2973">
          <ClassifiedCondition DB="MedGen" ID="C0026705">Mucopolysaccharidosis, MPS-II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-08-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-08-13" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">8940265</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9875019</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2973" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10834" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Attenuated MPS (subtype; formerly known as mild MPS II)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe MPS II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Iduronate 2-sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">I2S deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-II</ElementValue>
                <XRef ID="Mucopolysaccharidosis+type+II/4913" DB="Genetic Alliance" />
                <XRef ID="70737009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hunter Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IDS deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sulfoiduronate sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SIDS deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis with skin involvement</ElementValue>
                <XRef ID="MONDO:0019302" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 2</ElementValue>
                <XRef ID="MONDO:0010674" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS2</ElementValue>
                <XRef Type="MIM" ID="309900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS II</ElementValue>
                <XRef Type="MIM" ID="309900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6675" />
                <XRef ID="6675" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation. The vast majority of affected individuals are male; on rare occasion heterozygous females manifest findings. Age of onset, disease severity, and rate of progression vary significantly among affected males. In those with early progressive disease, CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease usually result in death in the first or second decade of life. In those with slowly progressive disease, the CNS is not (or is minimally) affected, although the effect of GAG accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in the slowly progressing form of the disease. Additional findings in both forms of MPS II include: short stature; macrocephaly with or without communicating hydrocephalus; macroglossia; hoarse voice; conductive and sensorineural hearing loss; hepatosplenomegaly; dysostosis multiplex; spinal stenosis; and carpal tunnel syndrome.</Attribute>
                <XRef ID="NBK1274" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301451</ID>
                <ID Source="BookShelf">NBK1274</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="PubMed">21863056</ID>
              </Citation>
              <Citation Type="general" Abbrev="Giugliani et al., 2014">
                <ID Source="PubMed">25071396</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/MPS-II.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Iduronate 2-Sulfatase Deficiency, Mucopolysaccharidosis Type II, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/MPS-II-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Mucopolysacchardosis Type II (MPSII): Decreased Iduronate 2-Sulfatase (I2S) activity, 2022</CitationText>
              </Citation>
              <XRef ID="580" DB="Orphanet" />
              <XRef ID="79388" DB="Orphanet" />
              <XRef ID="C0026705" DB="MedGen" />
              <XRef ID="MONDO:0010674" DB="MONDO" />
              <XRef Type="MIM" ID="309900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5917659" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="17300168|MedGen:C0026705" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003224982" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8940265</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9875019</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with IDS-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Leu58Trpfs*2) in the IDS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in IDS are known to be pathogenic (PMID: 8940265, 9875019).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDS" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.148585755del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0026705" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5917659" TraitType="Disease" MappingType="XRef" MappingValue="C0026705" MappingRef="MedGen">
        <MedGen CUI="C0026705" Name="Mucopolysaccharidosis, MPS-II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

